<table>
<thead>
<tr>
<th>Guideline Page and Request</th>
<th>Panel Discussion/References</th>
<th>Vote</th>
</tr>
</thead>
</table>
| **GAST-1, GAST-9, GAST-B (4 of 6)** | External request Submission from Promega Corporation (09/23/19) requesting the panel to equally emphasize any assay for the detection of microsatellite instability (MSI) that has been validated in gastric cancers be given equal weight and be recommended as a parallel technology with mismatch repair deficiency (MMR) protein expression analysis by immunohistochemistry (IHC) for gastric cancer patients. Based on the review of the data and discussion, the panel consensus was to include to emphasize analysis by IHC in the following pages of the guidelines: **GAST-1**  
- Workup: MSI-H/dMMR, MSI by PCR/MMR by IHC, and PD-L1 testing if metastatic disease is documented/suspected.  
**GAST-9**  
- Perform Her2, PD-L1, MSI-H/dMMR, MSI by PCR/MMR by IHC testing...  
**GAST-B (4 of 6)**  
- “MMR or Testing for MSI by polymerase chain reaction (PCR) or MMR by IHC testing should be considered on locally advanced…”  
- IHC for MMR and PCR for MSI are different assays measuring the same biological effect. PCR for MSI and IHC for MMR proteins measures different biological effects caused by dMMR function. | YES: 23, NO: 0, ABSTAIN: 0, ABSENT: 5 |